Stefan Anker, Robert Mentz, and Piotr Ponikowski discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for clinical practice and patients.
This video was distributed by our partner, ReachMD, a leading online learning platform for physicians and other healthcare professionals.
- Stefan D. Anker, MD, PhD - Division of Cardiology & Metabolism: Heart Failure, Cachexia and Sarcopenia, Department of Cardiology & BCRT, Berlin, Germany
- Robert J. Mentz, MD - Associate Professor, Chief, Heart Failure Section, Associate Program Director, Duke Cardiovascular Disease Fellowship, Durham, NC, US
- Piotr Ponikowski, MD, PhD - Medical University, Centre for Heart Disease, University Hospital in Wroclaw, Poland
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
This activity is supported by an independent educational grant from CSL Vifor.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Kidney Disease
Management of hyperkalemia in CKD and HFrEF
George L. Bakris, MD
David Bushinsky, MD
Lars Lund, MD
- Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
New insights on CETP inhibition from genetic research and clinical trials
John Kastelein, MD, PhD
Giuseppe M.C. Rosano, MD, PhD
Antoni Bayés-Genís, MD, PhD
Ovidiu Chioncel, MD, PhD
Ellie Kelepouris, MD
Stephen J. Greene, MD